ArticleScientific reports2025
Prospective registry study of single-isocenter dynamic conformal Arc SRS for multiple brain metastases.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- LINAC-based single-isocenter stereotactic radiotherapy for multiple brain metastases.Journal of radiation research · 2026Article
- Beyond the Scan: Adapting Multimodal Lung Cancer Screening for Central and Eastern Europe-Overcoming Systemic Barriers and Epidemiological Confounders.Medical sciences (Basel, Switzerland) · 2026Review
- Linac-based stereotactic radiosurgery for brain metastases: Survival and salvage treatment in a contemporary cohort of 3893 patients.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastases occur in 20-30% of patients with malignant tumors. While stereotactic radiosurgery (SRS) offers an effective treatment option for limited brain metastases, managing symptomatic patients with multiple metastases remains challenging due to prolonged treatment times and potential neurological complications. The dynamic conformal arc (DCA) SRS technique using a single-isocenter multi-target (DCA-SIMT) approach facilitates efficient treatment of numerous lesions. This study evaluates survival outcomes and symptom control in patients treated with DCA-SIMT SRS for multiple brain metastases. A registry based analysis was conducted on 123 patients with 560 metastatic CNS lesions treated with DCA-SIMT SRS at the Franciszek Lukaszczyk Oncology Center, Poland, between August 2018 and September 2020. The median survival time was 7.17 months. Patients were assessed for survival, local control, and treatment-related symptoms. Statistical analyses included Cox regression and Kaplan-Meier survival analysis. The 6-month and 12-month survival rates were 57% and 29%, respectively. Local control was achieved in 93% of lesions. The total planning target volume (PTV) was a significant prognostic factor (p = 0.008), with an increase in PTV associated with decreased survival. Patients with PTV ≤ 10 cm³ had significantly longer survival (p = 0.007). Histopathological subtype also influenced outcomes, with sqamous non-small cell lung cancer associated with poorer survival (p = 0.003). Neurological symptoms stabilized or improved in 61% of patients post-treatment, despite a median global V12 of 11.6 cm³, which was not associated with increased toxicity. DCA-SIMT SRS is a viable option for symptomatic patients with multiple brain metastases, offering rapid, precise treatment with significant clinical benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.